COMPARISON OF THE METABOLIC AND ENDOCRINE EFFECTS OF 3,5,3'-TRIIODOTHYROACETIC ACID AND THYROXINE

被引:52
作者
BRACCO, D [1 ]
MORIN, O [1 ]
SCHUTZ, Y [1 ]
LIANG, H [1 ]
JEQUIER, E [1 ]
BURGER, AG [1 ]
机构
[1] UNIV GENEVA, HOP CANTONAL, DIV ENDOCRINE, THYROID UNIT, CH-1211 GENEVA 4, SWITZERLAND
关键词
D O I
10.1210/jc.77.1.221
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To test the hypothesis that 3,5,3'-triiodothyroacetic acid (Triac) is more active as a TSH suppressor than on peripheral parameters of thyroid hormone action, the following parameters were studied: basal metabolic rate, sleeping energy expenditure (SEE), sex hormone-binding globulin, and cholesterol. In a double blind trial, 14 subjects received during 3 weeks (phase 1) 180 mug T4 or 1700 mug Triac daily, divided into 3 doses, to suppress thyroidal secretion. The dosage was doubled for the next 3 weeks (phase 2). Under T4 treatment, TSH reached 0.11 mU/L during phase 1 and less than 0.03 mU/L during phase 2. With Triac, a marked TSH inhibition occurred after 1 week (0.17 mU/L), followed by an escape during the following 2 weeks (0.63 mU/L). During phase 2, an almost complete TSH suppression was obtained (0.03 mU/L). Both Triac doses suppressed endogenous thyroid hormone secretion, as evidenced by T4 and rT3 levels. Both substances induced a 2-fold stimulation of sex hormone-binding globulin during phase 2. Serum cholesterol decreased similarly, without affecting the high/low density lipoprotein ratio. T4 increased SEE by 4.1% and 8.5% during phases 1 and 2. Triac failed to induce the expected peripheral metabolic responses of the thyroid hormones, as demonstrated by an unchanged SEE and basal metabolic rate. These results clearly show a preferential action of Triac on TSH suppression.
引用
收藏
页码:221 / 228
页数:8
相关论文
共 32 条
[11]   DIFFERENCES IN LIPOPROTEIN SUBFRACTION COMPOSITION AND DISTRIBUTION BETWEEN TYPE-I DIABETIC MEN AND CONTROL SUBJECTS [J].
JAMES, RW ;
POMETTA, D .
DIABETES, 1990, 39 (10) :1158-1164
[12]   LONG-TERM MEASUREMENTS OF ENERGY-EXPENDITURE IN HUMANS USING A RESPIRATION CHAMBER [J].
JEQUIER, E ;
SCHUTZ, Y .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1983, 38 (06) :989-998
[13]  
KUSHNER RF, 1992, J AM COLL NUTR, V11, P199
[14]   ESTIMATION OF ENERGY-EXPENDITURE, NET CARBOHYDRATE UTILIZATION, AND NET FAT OXIDATION AND SYNTHESIS BY INDIRECT CALORIMETRY - EVALUATION OF ERRORS WITH SPECIAL REFERENCE TO THE DETAILED COMPOSITION OF FUELS [J].
LIVESEY, G ;
ELIA, M .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1988, 47 (04) :608-628
[15]   ASSESSMENT OF FAT-FREE MASS USING BIOELECTRICAL IMPEDANCE MEASUREMENTS OF THE HUMAN-BODY [J].
LUKASKI, HC ;
JOHNSON, PE ;
BOLONCHUK, WW ;
LYKKEN, GI .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1985, 41 (04) :810-817
[16]   HORMONAL INFLUENCES ON OSTEOPOROSIS [J].
MCKENNA, MJ ;
FRAME, B .
AMERICAN JOURNAL OF MEDICINE, 1987, 82 (1B) :61-67
[17]   TRIAC (3,5,3'-TRIIODOTHYROACETIC ACID) HAS PARALLEL EFFECTS AT THE PITUITARY AND PERIPHERAL TISSUE-LEVELS IN THYROID-CANCER PATIENTS TREATED WITH L-THYROXINE [J].
MECHELANY, C ;
SCHLUMBERGER, M ;
CHALLETON, C ;
COMOY, E ;
PARMENTIER, C .
CLINICAL ENDOCRINOLOGY, 1991, 35 (02) :123-128
[18]   PHARMACOKINETICS OF 3,5,3'-TRIIODOTHYROACETIC ACID AND ITS EFFECTS ON SERUM TSH LEVELS [J].
MENEGAY, C ;
JUGE, C ;
BURGER, AG .
ACTA ENDOCRINOLOGICA, 1989, 121 (05) :651-658
[19]   3,5,3'-TRIIODOTHYROACETIC ACID MINIMIZES THE PITUITARY THYROTROPIN SECRETION IN PATIENTS ON LEVO-THYROXINE THERAPY AFTER ABLATIVE THERAPY FOR DIFFERENTIATED THYROID-CARCINOMA [J].
MUELLERGAERTNER, HW ;
SCHNEIDER, C .
CLINICAL ENDOCRINOLOGY, 1988, 28 (04) :345-351
[20]   INTRAINDIVIDUAL VARIABILITY AND MEASUREMENT NOISE IN ESTIMATES OF ENERGY-EXPENDITURE BY WHOLE-BODY INDIRECT CALORIMETRY [J].
MURGATROYD, PR ;
DAVIES, HL ;
PRENTICE, AM .
BRITISH JOURNAL OF NUTRITION, 1987, 58 (03) :347-356